Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

Xing Guo Wang, Thomas Jandl, Ekaterina Dadachova, Ekaterina Revskaya

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalTherapeutic Delivery
Volume5
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Heterografts
Uterine Cervical Neoplasms
Neoplasms
Cell- and Tissue-Based Therapy
Nude Mice
Cisplatin
Body Weight
Apoptosis
Injections
Therapeutics
Growth

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. / Wang, Xing Guo; Jandl, Thomas; Dadachova, Ekaterina; Revskaya, Ekaterina.

In: Therapeutic Delivery, Vol. 5, No. 2, 02.2014, p. 139-147.

Research output: Contribution to journalArticle

Wang, Xing Guo ; Jandl, Thomas ; Dadachova, Ekaterina ; Revskaya, Ekaterina. / Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. In: Therapeutic Delivery. 2014 ; Vol. 5, No. 2. pp. 139-147.
@article{1b117014ca6e4ee3858c03c64c15a497,
title = "Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice",
abstract = "Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4{\%} ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.",
author = "Wang, {Xing Guo} and Thomas Jandl and Ekaterina Dadachova and Ekaterina Revskaya",
year = "2014",
month = "2",
doi = "10.4155/tde.13.137",
language = "English (US)",
volume = "5",
pages = "139--147",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "2",

}

TY - JOUR

T1 - Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

AU - Wang, Xing Guo

AU - Jandl, Thomas

AU - Dadachova, Ekaterina

AU - Revskaya, Ekaterina

PY - 2014/2

Y1 - 2014/2

N2 - Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

AB - Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=84893241011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893241011&partnerID=8YFLogxK

U2 - 10.4155/tde.13.137

DO - 10.4155/tde.13.137

M3 - Article

C2 - 24483193

AN - SCOPUS:84893241011

VL - 5

SP - 139

EP - 147

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 2

ER -